Apixaban PK pecularities [PK / PD]

posted by BE-proff – 2022-03-14 21:17 (329 d 09:29 ago) – Posting: # 22836
Views: 804

Hi All,

According to Apixaban PIL its kinetics has some peculiarities::lookaround:

1) AUC is 32% higher in patients aged over 65
2) AUC is 18% higher in women
3) AUC is 30% higher in patients with body weight below 50 kilos.

Will it be correct to say (using extrapolation) that if a slim woman aged 70 takes 2.5 mg of apixaban the "actual dose" is close to 5.0 mg? :confused:

From the point of safety the question is important :wink:

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
24 visitors (0 registered, 24 guests [including 12 identified bots]).
Forum time: 06:47 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5